US President Donald Trump signed an executive order instructing federal agencies to adopt the term "Super Intelligence" instead of "Artificial Intelligence." Alongside the directive, major frontier AI developers signed a voluntary White House accord committing to safety guidelines, including internal and external reviews, third-party auditing, independent board oversight, and deployment controls.
Why it matters
The agreement relies on corporate self-governance rather than binding statutory restrictions or legal penalties. Because compliance is self-policing, any actual restraint on frontier model deployments depends entirely on voluntary adherence by signatory firms.
Bigger picture
The initiative signals a federal strategy prioritizing market-led oversight over centralized mandates, even as some tech executives and experts advocate formal regulatory boundaries for advanced AI capabilities.
Watch next
Watch for federal agency directives implementing the terminology change and whether participating developers publish details on their auditing protocols and board oversight mechanisms.
Donald Trump speaking at a podium during the 2016 AIPAC Policy Conference in Washington DC. · Lorie Shaull / Wikimedia CommonsCC BY-SA 4.0
What happened
US President Donald Trump has ruled out forming a joint artificial intelligence development venture between the United States and China. Trump also continues to push back against calls to establish regulatory guardrails on AI, arguing that safeguards would stifle economic growth.
Why it matters
The stance signals that US AI companies are unlikely to face immediate federal compliance costs or strict operational mandates. It indicates a policy prioritizing rapid commercial deployment over domestic safety guardrails and cross-border technology cooperation.
Bigger picture
Rejecting bilateral technology initiatives with Beijing reinforces a fragmented global AI landscape. Pairing minimal domestic regulation with economic nationalism encourages major powers to pursue independent AI capabilities without shared international governance.
Watch next
Watch for prospective executive directives from the White House detailing domestic AI policy and formal responses from foreign officials regarding international technology cooperation.
Get the day’s most important developments explained every morning. Subscribe and we’ll also send you The World, Explained—an India-first guide to economics, markets, business and geopolitics.
A Thermo Scientific UV-VIS spectrometer located in a professional pharmaceutical laboratory environment. · MediaLab TH Köln / Wikimedia CommonsCC BY-SA 4.0
What happened
The United States has announced zero import duties on select specialty medicines and components across 20 jurisdictions, including India. The decision waives a 100% tariff on products used for rare diseases, fertility treatments, and advanced therapies.
Why it matters
The exemption lowers import costs for critical treatments and preserves US market access for pharmaceutical manufacturers operating in India and the other designated regions.
Bigger picture
The targeted carve-out illustrates how regulators aim to safeguard vital healthcare supply chains while maintaining broader tariff policies across other economic sectors.
Watch next
Watch for detailed product lists from US authorities and subsequent adjustments to export volumes by affected drugmakers.
Get the day’s most important developments explained every morning. Subscribe and we’ll also send you The World, Explained—an India-first guide to economics, markets, business and geopolitics.
Make 7AM a habitPut the brief one tap from your morning.No app-store download. Opens like an app from your home screen.
Never miss the editionGet one quiet alert when the brief is ready.No breaking-news noise and no repeated notifications.
One alert after each edition is successfully published.
Worth forwarding?
Help one more person start informed.
If today’s brief saved you time, share it with someone who would value the same clarity.
